The case centered on a pediatric patient with confirmed macrolide-resistant Mycoplasma pneumoniae infection who had been placed on oral doxycycline, a standard and generally well-tolerated choice for this pathogen. After five days of treatment, laboratory testing revealed something alarming: the child’s activated partial thromboplastin time, or APTT, had climbed to more than twice the normal value. The APTT is one of the two central screening tests of the coagulation system, measuring how long it takes blood to clot through the intrinsic pathway, the cascade of proteins that acts when blood encounters damaged vessel walls. A doubling of that time is not a subtle laboratory blip; it signals a substantial slowing of the clotting machinery and, in some patients, a genuine risk of abnormal bleeding.

What made the finding particularly puzzling, and clinically important, was its isolation. In many coagulation disorders, both major screening tests go awry together: the prothrombin time, or PT, which measures the extrinsic pathway, and the APTT, which measures the intrinsic pathway, rise in tandem. Isolated APTT prolongation, with a normal PT, points the diagnostic finger in a narrower set of directions, toward problems with specific factors such as factor VIII, IX, XI or XII, toward the presence of certain inhibitors, or, as the authors of this report explore at length, toward disruptions in the vitamin K–dependent clotting system. The rarity of isolated APTT prolongation as a drug reaction is precisely why this case caught the attention of the clinical team.

To establish whether doxycycline was genuinely responsible, the researchers turned to the World Health Organization’s standardized causality assessment framework for adverse drug reactions, a structured method that weighs timing, alternative explanations, prior reports, and the response to drug withdrawal. Their conclusion: doxycycline was a likely cause of the child’s coagulation dysfunction. That formal designation matters, because distinguishing a drug reaction from the many other things that can disturb clotting in a sick child, including the infection itself, requires disciplined causal reasoning rather than suspicion alone. The consequences were tangible, too. The coagulation abnormality extended the patient’s hospital stay, which under standard pharmacovigilance definitions classifies the event as a serious adverse drug reaction, not merely an incidental laboratory curiosity.

The heart of the paper, and its most thought-provoking section, is the authors’ exploration of how a tetracycline antibiotic might interfere with blood clotting in the first place. Their analysis focuses on the vitamin K cycle, the biochemical loop that keeps the clotting system supplied with functional proteins. In that cycle, vitamin K must be converted to its active reduced form, vitamin K hydroquinone, by the enzyme vitamin K epoxide reductase, known as VKOR. Vitamin K hydroquinone then serves as the essential cofactor for gamma-glutamyl carboxylase, or GGCX, the enzyme that chemically modifies the vitamin K–dependent clotting factors so they can bind calcium and assemble into a working clot. When the cycle runs smoothly, factors II, VII, IX and X are continuously carboxylated and ready; when it falters, non-functional precursors accumulate and clotting slows.

This is, notably, the same pathway targeted by warfarin, the classic anticoagulant, which works by inhibiting VKOR and starving the clotting factors of their vitamin K–dependent activation. The report’s authors use this well-mapped biochemistry as the framework for hypothesizing how doxycycline might produce an isolated APTT prolongation, examining the vitamin K epoxide, the hydroquinone intermediate, and the enzymatic steps that link them. While the exact mechanism remains to be fully established, the discussion represents an unusually detailed mechanistic exploration for a single case report, reflecting the team’s concern that a rare reaction may be hiding in plain sight within one of medicine’s most common prescriptions. Because only some patients exposed to the drug develop the abnormality, any plausible mechanism would need to account for that selectivity, whether through individual differences in vitamin K status, metabolism, or the interplay with concurrent infection.

The clinical team did not work in a vacuum. The paper is anchored by a comprehensive review of the existing literature on doxycycline and coagulation, which confirmed just how rarely such reactions have been reported despite the drug’s enormous global footprint. That scarcity is a double-edged sword for clinicians: it offers reassurance that the reaction is uncommon, but it also means that most practitioners will never have encountered it and may not think to check for it. The authors’ conclusion is measured but pointed. Doxycycline-related coagulation abnormalities may be rare in the literature, they write, but the potential risk should not be overlooked, and vigilance is warranted, particularly in patients who already have underlying coagulation disorders or who are receiving anticoagulant medications at the same time.

That vigilance, in practical terms, translates into a specific and inexpensive recommendation: monitoring the APTT for early detection of the abnormality. The activated partial thromboplastin time is a routine, rapidly performed laboratory test available in virtually every hospital, which makes surveillance for this particular reaction far more feasible than surveillance for many other rare drug toxicities. For a child on doxycycline for resistant Mycoplasma pneumoniae, a periodic APTT could catch a developing coagulation dysfunction before it produces symptoms, allowing the drug to be stopped or the patient observed before bleeding complications arise. The authors’ suggestion is especially relevant in regions where macrolide resistance has made doxycycline a frontline therapy for large numbers of children, multiplying the number of exposures and, statistically, the opportunities for rare reactions to surface.

The broader significance of the report lies in the tension it highlights between a drug’s reputation and its pharmacology. Doxycycline earned its reputation for safety through decades of use, and nothing in this single case overturns that standing. But rare adverse reactions are, by their nature, invisible to ordinary clinical experience and emerge only through careful documentation of individual cases, the kind of pharmacovigilance that this report exemplifies. The event occurred in a patient treated at institutions in Guangzhou, with the study approved by the ethics committee of The Third Affiliated Hospital of Guangzhou Medical University under approval number LW-2025-141, and with written informed consent for publication provided by the patient’s mother. The research team included Yiyang Li, Si Huang, Liman Li, Weihua Li, Jian Gu and Lichun Xie, with contributions spanning the Third Affiliated Hospital of Sun Yat-sen University, the Third Affiliated Hospital of Guangzhou Medical University, and Foshan Fosun Chancheng Hospital.

Published online on 24 September 2026 as an open-access article in BMC Pediatrics, the paper arrives at a moment when macrolide-resistant Mycoplasma pneumoniae is increasingly prevalent and doxycycline prescriptions are climbing in step. For the clinicians prescribing it, the message is not to abandon the drug, which remains a first-line and generally safe treatment, but to recognize that even familiar medications can surprise us. A prolonged APTT in a child on doxycycline, particularly when the prothrombin time remains normal, should now join the differential diagnosis as a possible drug reaction rather than being dismissed as a laboratory oddity. For researchers, the case opens a mechanistic question, the precise interaction between tetracyclines and the vitamin K–dependent carboxylation pathway, that a single report cannot fully answer. And for the pharmacovigilance community, it is a reminder that the safety profile of any drug is never finished being written, and that attentive clinicians documenting unusual cases remain one of the most important early-warning systems in medicine.

Subject of Research: Doxycycline-associated isolated APTT prolongation and the vitamin K mechanism in a pediatric patient

Article Title: Pediatric doxycycline-induced isolated APTT prolongation: a rare case with exploration of the vitamin K mechanism

Article References: Li, Y., Huang, S., Li, L., Li, W., Gu, J., & Xie, L. (2026). Pediatric doxycycline-induced isolated APTT prolongation: a rare case with exploration of the vitamin K mechanism. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07536-5

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07536-5

Keywords: doxycycline, coagulation dysfunction, APTT, vitamin K, macrolide-resistant Mycoplasma pneumoniae, adverse drug reaction, pediatrics, antibiotics, VKOR, gamma-glutamyl carboxylase, pharmacovigilance, case report

The culprit, when it was finally identified, turned out to be not one pathogen but two. Metagenomic next-generation sequencing, or mNGS, performed on fluid sampled from deep within his lungs detected Chlamydia psittaci, an intracellular bacterium better known as the cause of psittacosis or parrot fever. Meanwhile, conventional sputum culture grew extended-spectrum beta-lactamase-producing Escherichia coli, a multidrug-resistant Gram-negative bacterium whose enzymes can dismantle many of the penicillin- and cephalosporin-class antibiotics that form the backbone of pneumonia therapy. The combination is genuinely rare. C. psittaci pneumonia is uncommon even on its own, typically tied to contact with infected birds, and its coexistence with a drug-resistant enteric bacterium in the same diseased lungs created a therapeutic puzzle that standard treatment guidelines are not built to solve.

The patient’s avian exposure was the first clue that many clinicians might have missed. Long-term contact with pigeons is a recognized risk factor for C. psittaci, which birds carry asymptomatically in their gastrointestinal tracts and shed in droppings, feather dust, and respiratory secretions. Humans inhale the organism in dried aerosols, and the resulting pneumonia can range from a mild flu-like illness to fulminant respiratory failure. Because the bacterium lives inside host cells and grows slowly, standard cultures often fail to detect it, and serological tests require paired samples taken weeks apart, a luxury that a deteriorating patient in an intensive care setting cannot afford. In this case, the initial workup was entirely unrevealing, and the man was begun on empiric therapy with piperacillin-tazobactam, a broad-spectrum beta-lactam and beta-lactamase inhibitor combination, plus doxycycline, the tetracycline-class antibiotic that is the traditional mainstay of psittacosis treatment.

On paper, that regimen should have covered both organisms. Piperacillin-tazobactam retains activity against many ESBL-producing E. coli strains, and doxycycline targets C. psittaci directly. Yet the patient failed to improve, a clinical signal that something in the equation was wrong. It was at this point that the diagnostic team turned to metagenomic next-generation sequencing, a technique that sidesteps the need to culture an organism at all. Instead of trying to grow a specific microbe, mNGS extracts all genetic material from a clinical sample, in this case bronchoalveolar lavage fluid suctioned through a bronchoscope into the deepest airways, and sequences it in bulk. Bioinformatic pipelines then subtract human reads and match the remaining fragments against databases of microbial genomes, producing an unbiased census of everything living in the sample, bacteria, viruses, fungi, and atypical organisms alike.

The sequencing results were decisive. C. psittaci DNA was detected in the lavage fluid, confirming the intracellular pathogen that routine diagnostics had missed, while the parallel sputum culture independently confirmed the ESBL-producing E. coli. The dual findings forced a reassessment of the entire treatment strategy. Antimicrobial susceptibility testing of the cultured E. coli provided the second half of the evidence, showing which antibiotics the resistant strain would and would not respond to. Guided by this combined molecular and phenotypic picture, the clinicians adjusted therapy to a three-drug regimen of piperacillin-tazobactam, doxycycline, and levofloxacin, a fluoroquinolone that adds activity against both atypical organisms and resistant Gram-negative bacteria. Alongside the antimicrobial escalation, the team provided respiratory support and organ protection, the supportive scaffolding that keeps patients alive long enough for antibiotics to work.

The response was what every clinician hopes for but cannot count on in sepsis. The patient improved steadily and was ultimately discharged, a resolution that the authors attribute directly to the treatment adjustment guided by mNGS and susceptibility data. The case thus becomes a textbook argument for molecular diagnostics in severe pneumonia of unknown origin, particularly when a patient fails empiric therapy. Traditional culture-based methods remain indispensable for susceptibility testing, but they are blind to organisms that will not grow on artificial media, and they can take days to yield results that a critically ill patient may not have. mNGS compresses that timeline and broadens the net, catching zoonotic and atypical pathogens that no standard panel would think to test for.

Yet the report also carries a cautionary note about over-reading molecular results, one that reflects a growing tension in the era of ultra-sensitive diagnostics. The authors emphasize that detecting a multidrug-resistant organism in a respiratory sample should be interpreted cautiously, weighing the possibility of colonization against true infection. The human airway and gut harbor complex microbial communities, and E. coli can colonize the respiratory tract of hospitalized patients without causing disease. Distinguishing a bystander from a pathogen requires clinical correlation, meaning the organism’s presence must fit the patient’s illness pattern, inflammatory markers, imaging, and, crucially, the response to targeted therapy. In this case, the treatment failure on the initial regimen and the eventual improvement after adjustment served as the real-world test of whether the ESBL-producing E. coli was a genuine co-pathogen or an innocent passenger, and the clinical trajectory argued for its relevance.

The broader lesson extends beyond this single hospital room. Severe community-acquired pneumonia remains one of the most common reasons for intensive care admission worldwide, and a substantial fraction of cases never receive a confirmed etiological diagnosis, forcing clinicians into empiric choices that can miss atypical organisms or underestimate resistance. Patients with animal exposure, whether birds, livestock, or wildlife, represent a subgroup where the differential diagnosis widens considerably, encompassing zoonoses such as psittacosis, Q fever, and tularemia that routine testing rarely covers. The authors argue that in such patients who fail initial therapy, mixed infections including drug-resistant bacteria must be actively considered rather than assumed away, and that rapid etiological diagnosis through mNGS can meaningfully redirect care. The finding also underscores the quiet global march of ESBL-producing Enterobacterales, which have moved from hospital wards into community settings, meaning that resistance genes once confined to healthcare-associated infections can now appear in a farmer’s lungs.

For the individual patient, the story ended well, a 71-year-old man with respiratory failure and sepsis walking out of the hospital after a diagnostic odyssey that conventional tools could not resolve. For the field, the case adds to a mounting body of evidence that the future of severe pneumonia diagnosis is untargeted, sequencing-based, and paired with disciplined clinical interpretation. The technique is not without limitations, including cost, turnaround variability, contamination risk, and the persistent difficulty of distinguishing colonization from infection, but as this report demonstrates, when a patient with bird exposure deteriorates despite seemingly appropriate antibiotics, the answer may be hiding in two organisms at once, and only an unbiased look at the lung’s microbial census will reveal it.

Subject of Research: A case report of severe community-acquired pneumonia involving co-infection with Chlamydia psittaci and ESBL-producing Escherichia coli diagnosed by metagenomic next-generation sequencing.

Article Title: Severe community-acquired pneumonia complicated by co-infection with Chlamydia psittaci and ESBL-producing Escherichia coli: a case report

Article References: Lu, C., Xie, T., Xu, B., Li, Y., & Yurui, Y. (2026). Severe community-acquired pneumonia complicated by co-infection with Chlamydia psittaci and ESBL-producing Escherichia coli: a case report. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14001-2

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14001-2

Keywords: Chlamydia psittaci, psittacosis, community-acquired pneumonia, ESBL-producing Escherichia coli, metagenomic next-generation sequencing, antimicrobial resistance, sepsis, respiratory failure, avian exposure, bronchoalveolar lavage, doxycycline, case report

The motivation for the sensing half of the work stems from an escalating global concern. Doxycycline, a second-generation tetracycline antibiotic, is prized in human and veterinary medicine and in animal husbandry for its broad-spectrum antibacterial action, low cost, and its historical use as a growth promoter. Yet because animals and humans metabolize it incompletely, the drug persists in water, soil, and animal-derived foods such as milk, meat, and eggs. Chronic exposure to residual doxycycline has been linked to allergic reactions, gastrointestinal disturbances, and liver toxicity, and, more alarmingly, it fuels the rise of antibiotic-resistant bacteria, a mounting public health crisis. Regulatory bodies, including the European Union, have consequently imposed strict maximum residue limits in foodstuffs, such as 100 micrograms per kilogram in meat and milk, creating urgent demand for rapid and reliable detection methods.

Conventional analytical techniques for doxycycline, including high-performance liquid chromatography, immunoassays, and spectrophotometry, deliver good accuracy but come with significant burdens. They typically demand expensive instrumentation, laborious and time-consuming sample pretreatment, and skilled personnel, and they are poorly suited to rapid on-site analysis. Fluorescence sensing has therefore emerged as an attractive alternative, offering high sensitivity, fast response, operational simplicity, and low cost. Within this landscape, carbon dots have attracted particular attention thanks to their excellent photostability, low toxicity, good biocompatibility, easy synthesis, and tunable photoluminescence. Crucially, their surfaces can be functionalized to interact selectively with target molecules, making them ideal candidates for designing probes that respond to specific analytes such as doxycycline.

The Lyuliang team pushed the concept further by doping their carbon dots with three heteroatoms at once. The synthesis is strikingly straightforward: 0.2 grams of 3,4-difluorophenylboronic acid and 0.2 milliliters of ethylenediamine are dissolved in ultrapure water and heated in a Teflon-lined stainless-steel autoclave at 180 degrees Celsius for seven hours. After filtering through a 0.22 micrometer membrane and lyophilizing the filtrate, the researchers obtained a yellow powder of B/F/N-co-doped carbon dots. Transmission electron microscopy revealed quasi-spherical nanoparticles averaging about 3.24 nanometers in diameter, while atomic force microscopy confirmed good dispersion with particle heights predominantly between 2.0 and 2.5 nanometers.

Spectroscopic characterization confirmed that all three dopants had been successfully incorporated into the carbon matrix. Fourier transform infrared spectroscopy identified hydroxyl, C-H, carbonyl, C-N, and mixed C-F/C-O/C-B stretching features, while X-ray photoelectron spectroscopy detected characteristic signals for carbon, nitrogen, oxygen, boron, and fluorine, with high-resolution deconvolution revealing C-B, C=O, C-F, C-N, N-H, and B-N bonding environments. Optically, the dots absorb strongly at 266 and 236.5 nanometers, corresponding to pi-pi* transitions of carbon-carbon double bonds, and emit bright green fluorescence at 510 nanometers when excited at 410 nanometers. The fluorescence quantum yield reached 11.12 percent using quinine sulfate as a reference. Notably, the dots maintained their fluorescence across wide ranges of pH and salt concentration and under continuous ultraviolet irradiation, though exposure to high concentrations of hydrogen peroxide cut the emission roughly in half through oxidative disruption of the conjugated structure.

When doxycycline was titrated into the dot solution, the green glow dimmed steadily with increasing antibiotic concentration. The response was linear between 0.138 and 0.421 millimolar, following the relationship 1-F/F0 equals 2.32065c(DOX) minus 0.16669 with a correlation coefficient of 0.9965, and the calculated limit of detection was 3.1 micromolar. The entire reaction completed within eight minutes, and critically, the probe showed strong selectivity: a panel of structurally or functionally related drugs produced minimal fluorescence changes, while doxycycline triggered a pronounced drop. Applied to spiked tap water and river water samples collected near Lyuliang City using the standard addition method, the sensor delivered recoveries between 97.79 and 102.77 percent with relative standard deviations no higher than 4.45 percent, demonstrating genuine practical accuracy and reproducibility for environmental water analysis.

The physical origin of the quenching was dissected through fluorescence lifetime measurements. Upon adding doxycycline, the average lifetime of the excited dots shortened from 4.13 nanoseconds to 3.47 nanoseconds, a hallmark of dynamic, or collisional, quenching. The researchers also examined the spectral overlap between doxycycline’s absorption and the excitation profiles of the dots and found it negligible, effectively ruling out both the inner filter effect and Forster resonance energy transfer. Instead, the data point to direct collisions between photoexcited carbon dots and doxycycline molecules, which facilitate electron transfer followed by non-radiative relaxation to the ground state, dissipating the excitation energy as heat rather than light.

The second, more surprising application emerged when the dots were blended into poly(vinyl alcohol), a hydrophilic polymer that burns readily. After mixing an aqueous dot solution into a 7.5 weight percent PVA solution, casting the mixture into films, and drying them, the team subjected rectangular specimens to vertical burning tests. While both pure PVA and the composite behaved similarly after the first ignition, the differences appeared on re-ignition: the after-flame time of the composite dropped to 5.2 seconds compared with 9.7 seconds for pure PVA, and the afterglow time shrank to a negligible 0.2 seconds. In practical terms, the doped films extinguished themselves markedly faster, a meaningful improvement in the self-extinguishing behavior of a widely used polymer.

The flame-retardant mechanism, the authors explain, is a synergy of gas-phase and condensed-phase effects. During combustion, the carbon dots promote the formation of a continuous, dense char layer on the polymer surface that acts as a physical barrier, slowing heat and oxygen transfer while trapping combustible gases. The C-N, N-H, and B-N groups identified by XPS and FTIR can thermally decompose to release inert gases such as ammonia and nitrogen, diluting the flammable atmosphere and interfering with radical-chain reactions in the gas phase. Boron-containing species contribute a stable, oxide-rich surface layer that further retards heat and mass transfer, while fluorine, locked into robust C-F bonds, strengthens the char residue by suppressing crack formation and enhancing its barrier performance.

Together, the results position heteroatom co-doping as a versatile and economical strategy for designing carbon dots with dual roles in optical sensing and fire-safe materials. Given that the synthesis requires only a single hydrothermal step with inexpensive reagents, and that the sensing platform already performs reliably in real environmental waters, the approach could plausibly extend to portable doxycycline monitoring kits and to polymer composites where both fluorescence and flame resistance are valued. As antibiotic pollution and fire safety continue to loom as intertwined materials-science challenges, this unassuming yellow powder of doped carbon dots illustrates how cleverly engineered nanomaterials can answer two pressing questions at once.

Subject of Research: Development of B/F/N co-doped carbon dots for fluorescent doxycycline sensing and flame-retardant polymer applications.

Article Title: B/F/N Co-doped carbon dots as a fluorescent probe for doxycycline and flame retardant performance

Article References: Zhang, T., Cai, T., Yu, T., Han, X., Sun, Q., & Qi, G. (2026). B/F/N Co-doped carbon dots as a fluorescent probe for doxycycline and flame retardant performance. Journal of Saudi Chemical Society, 30(4), Article 62. https://doi.org/10.1007/s44442-026-00112-7

Image Credits: AI Generated

DOI: 10.1007/s44442-026-00112-7

Keywords: carbon dots, doxycycline, fluorescent probe, heteroatom doping, dynamic quenching, flame retardant, poly(vinyl alcohol), water quality, antibiotic residues, fluorescence sensing, Co-doped, carbon